Page 88 - Badan POM Terbitkan PPUK Vaksin COVID-19 GX-19N

Judul :Kalbe Farma to conduct clinical testing for GX-19N COVID-19 vaccine in
Indonesia

Nama Media : Idnfinancials.com
Tanggal : 12 Juli 2021

Halaman/URL:https://www.idnfinancials.com/news/39727/kalbe-farma-conduct-
clinical-testing-gx-n-covid-vaccine-indonesia

Tipe Media : Online

JAKARTA. PT Kalbe Farma Tbk (KLBF)
has obtained approval from the National
Agency of Drug and Food Control
(BPOM) for its clinical testing of 2b/3
stage of the GX-19N COVID-19 vaccine
in Indonesia. It is targeted to be
completed by the end of 2021.

Irawati Setiady, President Commissary
of Kalbe Farma, states that the GX-19N
development would be continued considering the COVID-19 vaccine supply in
Indonesia has not yet met the public’s demand. “Should the 2b/3 stage testing be
deemed successful and gain an emergency use authorisation from BPOM, the GX-
19N would add to the existing vaccine supply,” he confirms in the press conference
received by idnfinancials.com.

Once the clinical testing of GX-19N generated adequate results and obtained the
emergency use authorisation, the new vaccine would become an alternative to other
existing COVID-19 vaccines in Indonesia. KLBF has promised to provide 10 million
doses of the GX-19N vaccine.

GX-19N is a vaccine developed by Kalbe Farma and Genexine, a pharmaceutical
company based in South Korea. Other pharmaceutical companies also participate in
this vaccine development consortium. The previous stages of testing, 1 and 2a, had
been performed in South Korea.

For this current 2b/3 phase, the clinical testing would also be conducted in several
countries, such as Turkey, India, UAE, Mexico, etc. The total volunteers participating
in this stage reach over 30 thousand people.